medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 2

<< Back Next >>

Rev Invest Clin 2006; 58 (2)

Anticuerpo a hepatitis C: ¿verdadero o falso positivo? Nuevas estrategias de diagnóstico

Contreras AM

Language: Spanish
References: 23
Page: 153-160
PDF size: 73.21 Kb.


Text Extraction

No abstract


REFERENCES

  1. Coo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.

  2. Pawlotsky JM. Use and Interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73.

  3. Alter MJ, Kuhnert WL, Finelli L. Center for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Center for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1-13.

  4. Richter S. Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microb 2002; 12: 4407-12.

  5. Chapko MK, Sloan KL, Davidson JW, Dufour R, Bankson DD, Rigsby M, et al. Cost effectiveness of testing strategies for chronic hepatitis C. Am J Gastroenterol 2005; 100; 607-15.

  6. Tobler LH, Tegtmeier G, Stramer SL, Quan S, Dockter J, Giachetti D, et al. Lookback on donors who are repeatedly on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000; 40(1): 15-24.

  7. Payan C, Raimbert A, Fouchard-Hubert I, Kouyoumdjian S, Lunel- Fabiani F. Quantitative antibody analysis: use for the diagnosis of hepatitis C virus chronic infection. Ann Biol Clin 2003; 3: 311-17.

  8. Sookian S, Castaño G. Evaluation of a third generation anti- HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 2002; 1(4): 179-82.

  9. Dufour RD, Talastas M, Fernandez DAM, Harris B. Chemiluminescence assay improves specificity of hepatitis C antibody detection. Clin Chemistry 2003; 6: 940-4.

  10. Dufour DR, Talastas F, Harris B, Strader BD, Seeff BL. Low- Positive anti-Hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection. Clin Chem 2003; 3: 479-83.

  11. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Mita E, Ohkawa K, et al. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis c virus infection. Hepatology 1996; 5: 947-52.

  12. Sik Kim Y, Lee HS, Ahn YO. Factors associated with positive predictability of the anti-HCV ELISA method with confirmatory RT-PCR. J Korean Med Sci 1999; 14: 629-34.

  13. Méndez SN, Aguilar RJ, Reyes A, Dehesa M, Juárez A. Castañeda B, et al. Etiology of liver cirrosis in Mexico. Ann Hepatol 2004; 3: 30-3.

  14. Secretaría de Salud. Dirección General de Información en Salud. Elaborado a partir de la base de datos de defunciones INEGI/Secretaría de Salud 2002.

  15. Marin RA, López SR, Infante RL, Méndez AJ, Berrón RP, Morales AN, et al. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Transfusion 2004; 44: 1344-9.

  16. Vivas AC, Aguilar BS, Trujillo J, Panduro A, Rivas EA. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Research 2003; 25: 115-23.

  17. National Institutes of Health. Consensus Development Conference. Management of Hepatitis C. Hepatology 2002; 36(5) Suppl. 1: S1-S252.

  18. Polywka S, Schroter M, Feucht HH, Zollner B, Laufs R. Relevance of reactivity in commercially available hepatitis C virus antibody assays. J Clin Microbiol 1999; 37: 233-4.

  19. Seed CR, Margaritis AR, Bolton VW, Kiely P, Parker S, Piscitelli L, et al. Improved efficiency of national HIV, HCV and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion 2003; 43: 226-34.

  20. Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential thirdgeneration immunoassays. Transfusion 2004; 44: 349-58.

  21. Vitros anti-HCV. Ortho-Clinical Diagnostics, Johnson and Johnson Company, 2003, Amersham, Bucks. United Kingdom.

  22. Simonovic J, Dokie Lj, Svirtlih N, Djordjevic M, Bozic N, Polunga J. Autoimmune hepatitis and/or hepatitis C. Srp Arch Celok Lek 1999; 127: 109-13.

  23. Vella FS, Orlando P, Attanasi F, Simone B, Mundo A, Lopalco P, et al. Autoantibodies in chronic hepatitis C. markers o autoimmunity or non-specific events? Recenti Prog Med 2001; 92(2): 107-12.




2020     |     www.medigraphic.com